| Autor: |
Vandikas MS; Dermatology and Venereology Unit, Karolinska University Hospital, Solna, Eugeniavägen 3, A6:01, SE-171 76, Stockholm, Sweden. maria.s.vandikas@gu.se., Landin-Wilhelmsen K, Polesie S, Gillstedt M, Osmancevic A |
| Jazyk: |
angličtina |
| Zdroj: |
Acta dermato-venereologica [Acta Derm Venereol] 2021 Nov 24; Vol. 101 (11), pp. adv00604. Date of Electronic Publication: 2021 Nov 24. |
| DOI: |
10.2340/actadv.v101.359 |
| Abstrakt: |
High levels of serum vitamin D-binding protein have been shown previously in patients with psoriasis compared with healthy controls; a possible role in inflammation is implied. The primary objective of this study was to investigate the impact of 24-week etanercept treatment on vitamin D status and vitamin D-binding protein in patients with psoriasis. The secondary aim was to explore whether pre-treatment vitamin D levels could predict the treatment effect. A prospective observational study was performed, including 20 patients with psoriasis and 15 controls. Serum samples were analyzed for, among others, vitamin D metabolites, vitamin D-binding protein and highly sensitive C-reactive protein. Baseline levels of vitamin D-binding protein were higher in patients with self-reported arthropathy than in those without. After 24 weeks' treatment, an improvement in psoriasis was noted, as was a decrease in highly sensitive C-reactive protein. Vitamin D-binding protein decreased in those with self-reported arthropathy. Higher baseline levels of vitamin D were associated with faster and greater improvement in psoriasis. Vitamin D-binding protein may have an inflammatory biomarker role. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
